BioUtah News – Page 83

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

Posted on August 4, 2021 by Press Release

Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched a new version of its market-leading MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the market’s most accurate hereditary cancer test. […]

Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

Posted on August 3, 2021 by admin

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2021 and provided an update on recent business performance and strategic transformation plans. […]

SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial

Posted on July 30, 2021 by Denise Bell

PolarityTE on July 28 announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers (DFU) with its investigational product SkinTE®. The trial met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction (PAR) assessed at 4, 6, 8, 10, and 12 weeks. Nikolai […]

PolarityTE Receives Notice of Allowance for Chinese Patent

Posted on July 30, 2021 by Denise Bell

PolarityTE recently announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Application No. 201580075326.3. The allowed claims relate to skin-regenerative compositions utilizing PolarityTE’s minimally polarized functional unit (MPFU) technology as well as methods of making a skin-regenerative composition utilizing the MPFU technology. This most recent allowance further […]

PolarityTE Submits Investigational New Drug Application for SkinTE®

Posted on July 30, 2021 by Denise Bell

PolarityTE on Monday announced the submission of an investigational new drug application (IND) to the FDA seeking authorization to commence a clinical trial to evaluate its SkinTE product for the proposed indication of treatment of chronic cutaneous ulcers. SkinTE is PolarityTE’s human cellular and tissue-based product derived from a patient’s own skin. David Seaburg, Chief Executive […]

Foldax Presents at the 2021 Transcatheter Valve Technologies Meeting

Posted on July 30, 2021 by Denise Bell

Last week, Foldax presented on the company’s innovative Tria valve at the 2021 Transcatheter Valve Technologies (TVT) meeting. View the slides HERE. The presentation titled “Foldax Biopolymer Valves: An Alternative to Tissue Based Leaflet Valves” was given by Foldax investigator, Dr. David Heimansohn, chief of surgery at St. Vincent/Ascension in Indiana and was well received. […]

Senator Mike Lee Tours Stryker Neurovascular Division

Posted on July 23, 2021 by Denise Bell

U.S. Senator Mike Lee (R-UT) on July 16 toured Stryker’s Neurovascular Division with division President, Mark Paul, joined by BioUtah President and CEO, Kelvyn Cullimore and members of the Senator’s staff. During the tour, Lee learned about the innovative, best-in-class technologies manufactured at the Salt Lake City facility to treat stroke patients. Stroke is the […]

Co-Diagnostics Strengthens IP Portfolio with New International CoPrimer™ Patent

Posted on July 23, 2021 by Denise Bell

Co-Diagnostics has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea’s Intellectual Property Office for the Company’s CoPrimer™ technology. Developed in 2013, Co-Diagnostics’ solely-owned CoPrimer technology received its first patent from the US Patent Office in 2018, and underpins the company’s molecular diagnostic test products that […]

Biosafety Startup, R-Zero Acquires Leading Workplace Intelligence Platform, CoWorkr

Posted on July 23, 2021 by Denise Bell

South Salt Lake-based R-Zero, the first biosafety technology company dedicated to creating safer, healthier indoor spaces, announced July 20 its acquisition of CoWorkr, the leading property technology company offering privacy-first space utilization sensors for data-driven workplaces. Fresh off its Series B raise closed in June, R-Zero’s first acquisition accelerates speed to market for an IoT […]

Owlet to Begin Trading on the New York Stock Exchange

Posted on July 23, 2021 by Denise Bell

Owlet on July 15 announced that it completed its business combination with Sandbridge Acquisition Corporation, a special purpose acquisition company (SPAC) as previously announced in February. Following the transaction, the company was renamed Owlet, Inc, and its Class A common stock and warrants began trading on the New York Stock Exchange under the symbols “OWLT” […]

Sera Prognostics Announces Pricing of Initial Public Offering

Posted on July 23, 2021 by Denise Bell

Sera Prognostics – The Pregnancy Company® – located in Salt Lake City, Utah, has announced the pricing of its initial public offering of 4,687,500 shares of its common stock at a price to the public of $16.00 per share. Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies […]

Utah Based MMV Launches Second Healthcare Fund

Posted on July 23, 2021 by Denise Bell

MMV, a Salt Lake City-based seed-stage venture capital firm, announced the first close of its second fund, MMVII. The fund will be managed by Managing Partners Branden Rosenhan, MD, Saumitra Thakur, MD and General Partner and COO Katelin Roberts. “95% of our first fund investors have joined us in MMVII, many stepping up their commitments. […]